Nanobiotix share rebounds, +12.5% in one week but -25.5% over one month
The Parisian biotech company specializing in oncological nanomedicine rebounded sharply in mid-session, in an SBF 120 oriented upwards. This surge occurs following a very heavy monthly sequence that wiped out its main technical benchmarks, while the share remains close to its recent lows.
A rebound that has not yet brought the share above its moving averages
At €22.20, Nanobiotix gains 4.72% in the session and climbs approximately 12.8% over one week, but the share still loses 25.65% over one month. The price remains below the 20-day moving average (€23.42, a gap of 5.21%) as well as the 50-day moving average (€29.46), which places the rebound in the continuation of a larger decline. The RSI at 37 describes a share that has evacuated a large part of selling pressure without being in outright oversold territory.
Support is found at €18.85, approximately 15% below the current price, while resistance at €31.30 remains distant. This movement is that of a security detaching itself in a supportive market: the SBF 120 advances 0.51% and the CAC 40 by the same measure, while the share gains nearly ten times more. The day's ranking places it among the strongest gains in the index.
A cash position of €110.9 million financing operations through 2029
During the publication of its operational update for the first half of 2026, on September 24, the company stated it had €110.9 million in cash, compared to €52.8 million at the end of December 2025, following a capital increase of approximately €86 million completed in May. It estimates that these liquid assets will allow it to finance its operations through 2029. The company's activities center on the radioamplifier NBTXR3 (JNJ-1900), associated with radiotherapy and developed in partnership with Johnson & Johnson.
The share is listed both in Paris and on the Nasdaq in ADS form, at a ratio of one ADS to one ordinary share: the two lines generally move on the same day, and only the Paris share is eligible for the PEA. Regarding analyst opinions on Nanobiotix, the consensus remains available on our site.
